Chronic myeloid leukemia (CML) is defined by the presence of t(9;22)(q34;q11.2)/BCR-ABL1. Additional chromosomal abnormalities confer an adverse prognosis and are particularly common in the blast phase of CML (CML-BP). CBFB rearrangement, particularly CBFB-MYH11 fusion resulting from inv(16)(p13.1q22) or t(16;16)(p13.1;q22), is an acute myeloid leukemia (AML)-defining alteration that is associated with a favorable outcome. The co-occurrence of BCR-ABL1 and CBFB rearrangement is extremely rare, and the significance of this finding remains unclear. We identified 10 patients with myeloid neoplasms harboring BCR-ABL1 and CBFB rearrangement. The study group included six men and four women with a median age of 51 years (range, 20-71 years). The sequence of molecular alterations could be determined in nine cases: BCR-ABL1 preceded CBFB rearrangement in seven, CBFB rearrangement preceded BCR-ABL1 in one, and both alterations were discovered simultaneously in one patient. BCR-ABL1 encoded for p210 kD in all cases in which BCR-ABL1 preceded CBFB rearrangement; a p190 kD was identified in the other three cases. Two patients were treated with the FLAG-IDA regimen (fludarabine, cytarabine, idarubicin, and G-CSF) and tyrosine kinase inhibitors (TKI); seven with other cytarabine-based regimens and TKIs, and one with ponatinib alone. At last follow up (median, 16 months; range 2-85), 7 of 10 patients had died. The co-existence of BCR-ABL1 and CBFB rearrangement is associated with poor outcome and a clinical course similar to that of CML-BP, and unlike de novo AML with CBFB rearrangement, suggesting that high-intensity chemotherapy with TKI should be considered in these patients.
The occurrence of additional cytogenetic alterations other than t (9;22) is observed in up to 80% of cases of CML-BP. [6] [7] [8] [9] [10] [11] [12] The most common additional cytogenetic abnormalities include trisomy 8, an extra copy of the Ph chromosome, 3q26 rearrangements, monosomy 7/del(7q), i(17)(q10), trisomy 21, minus Y, and trisomy 19. 6, 7 CBFB rearrangement, particularly CBFB-MYH11 fusion, resulting from inv(16)(p13.1q22) or less commonly t(16;16)(p13.1;q22), is an acute myeloid leukemia (AML)-defining alteration that is associated with a favorable outcome. [13] [14] [15] CBFB is a member of the core binding factor (CBF) family of transcription factors and stabilizes the interaction of the a subunits RUNX1, RUNX2, and RUNX3 with DNA. RUNX1
regulates hematopoietic stem cell self-renewal, survival, and differentiation of B-cells, T-cells, and megakaryocytes. The fusion product encodes the protein CBFB-SMMHC which is thought to be necessary but insufficient for the development of AML. The fusion protein induces defective hematopoietic differentiation; however, usually additional genetic alterations, mostly mutations, are needed for fully developed leukemogenesis. 16 CBFB-SMMHC induces a dominant negative effect on wild-type CBFB via its more potent binding ability to RUNX, thereby repressing RUNX1. More recently, it has been suggested that the CBFB-SMMHC fusion protein cooperates with RUNX1 to act as a transcription activator and induce differential gene expression. 16 Because of the variability of the genomic breakpoints in CBFB and MYH11 over 10 fusion products of different sizes have been described.
The most common form is type A, occurring in more than 85% of cases; type D and E are seen in up to 5%-10% of cases and other fusion forms have been reported in isolated cases. 17 The co-occurrence of BCR-ABL1 fusion and CBFB rearrangement is extremely rare and its clinical significance remains largely unknown. [18] [19] [20] [21] Since therapeutic approaches to neoplasms harboring these potent oncogenic fusion products are different, the co-occurrence of BCR-ABL1 fusion and CBFB rearrangement might pose a clinical management challenge.
Herein, we describe a series of patients with myeloid neoplasms harboring BCR-ABL1 fusion and CBFB rearrangement and provide detailed clinicopathologic details, genotype-phenotype correlation, and outcome data.
| M E T H O D S

| Patients and study design
We identified retrospectively 10 patients with AML carrying both BCR-ABL1 and CBFB rearrangement seen and treated at The University of Texas MD Anderson Cancer Center (UTMDACC). These patients included a subset with a well-documented antecedent CML in chronic phase and another group that harbored both alterations at the time of initial diagnosis. Clinical and laboratory data were obtained by electronic chart review.
This study was approved by the Institutional Review Board of UTMDACC and was conducted in accordance with the declaration of Helsinki.
| Morphologic evaluation
All diagnostic BM samples were reviewed. BM cellularity was assessed relative to age according to the EUMNET criteria. 22 BM blast, eosinophil, and monocyte percentages were enumerated by a 500-cell count using Wright-Giemsa-stained aspirate smears and/or touch imprints.
| Flow cytometry immunophenotyping
Multiparameter flow cytometry was performed on BM samples using a standard stain-lyse-wash procedure with ammonium chloride lysis and the FACSCanto II cytometer and FACSDiva software (BD Biosciences).
Data were analyzed using FCS Express (De Novo Software, Glendale, CA). The following antibodies were used in various combinations: CD2,   sCD3, cytoCD3, CD4, CD5, CD7, CD13, CD14, CD15, CD19, CD22,   CD25, CD33, CD34, CD36, CD38, CD41, CD45, CD56, CD64, CD117, CD123, HLA-DR, MPO, and TDT.
| Cytogenetic analysis
Conventional cytogenetic analysis was performed on unstimulated cultured BM aspirate specimens using standard GTG-banding as described previously. 23 At least 20 metaphases were analyzed. Results were reported using the 2013 International System for Human Cytogenetic Nomenclature (ISCN). breakapart probes (Abbott Molecular/Vysis, Des Plaines, IL) using previously described methods. 18 A total of 200 interphases were analyzed.
The positive cutoff value of 2.0% for BCR/ABL1 rearrangement and 4.2% for CBFB rearrangement has been established in our laboratory.
| Quantitative reverse transcription PCR for BCR-ABL1 and CBFB-MYH11
Reverse transcription quantitative polymerase chain reaction (Q-PCR) for detection of BCR-ABL1 and CBFB-MYH11 was performed using RNA extracted from BM or PB samples according to methods described previously. 25, 26 Briefly, the BCR-ABL1 Q-PCR is a multiplex assay designed to detect the e1a2, e13a2 (b2a2), and e14a2 (b3a2) transcripts in a single tube. BCR-ABL1 and ABL1 transcript levels were detected simultaneously and quantitative results were expressed as the percent ratio of BCR-ABL1
to ABL1. The specific fusion transcripts were distinguished using capillary electrophoretic separation of the fluorochrome-labeled products. The CBFB-MYH11 assay is designed to detect type A CBFB-MYH11 fusion transcript. 26 The CBFB-MYH11 was also normalized to ABL1 transcript levels for quantification. The sensitivity of detection of BCR-ABL1 and CBFB-MYH11 transcripts was between 1 in 10,000 and 1 in 100,000.
| Mutation analysis
Mutation analysis was performed using DNA extracted from BM aspirate samples in a subset of patients using the following techniques: Next-generation sequencing-based mutation analysis of exonic regions of ABL1, EGFR, GATA2, IKZF2, MDM2, NOTCH1, RUNX1, ASXL1, EZH2, HRAS, JAK2, MLL, NPM1, TET2, BRAF, IDH1, KIT, NRAS, TP53, DNMT3A, GATA1, IDH2, KRAS, MYD88, PTPN11, and WT1 was performed using the Illumina MiSeq (Illumina, San Diego, CA) sequencer as described previously. 27 FLT3 (internal tandem duplication and D835) and NPM1
(exon12, codons 956-971) mutations were assessed by polymerase chain reaction (PCR) followed by capillary electrophoresis on a Genetic
Analyzer (Applied Biosystems, Foster City, CA), as described previously. 28 In some cases, mutations in NRAS and KRAS (codons 12, 13, and 61), and KIT exon 17 (codons 778 to 838) were analyzed using pyrosequencing (Biotage, Uppsala, Sweden). PCR-based cDNA sequencing of BCR-ABL1 was performed to detect mutations in codons 221 to 500 of the ABL1 kinase domain, including codon 315.
| R E S U LTS
| Clinical and laboratory findings
The salient clinical features for the 10 patients are summarized in Table 1 .
There were six (60%) men and four (40%) women with a median age of 
| Morphologic features
The median BM cellularity was 90% (range, 30-100%). The median BM blast and eosinophil percentages were 26% (range, 20-87%) and 8%
(range, 2-30%), respectively, at the time of BCR-ABL1 and CBFB rearrangement co-occurrence. The median BM monocyte percentage was 3% (range, 0-26%). Morphologically abnormal eosinophils and eosinophilic precursors with immature eosinophilic granules were identifiable in 6 of 10 cases. (Figures 1 and 2) 
| Flow cytometry immunophenotyping results
Aberrant myeloid blasts were identified in all cases (n 5 9) with available data. The most common alterations included increased expression of CD13 and decreased expression of CD33, CD38, and HLA-DR. Flow cytometric immunophenotyping details for each case are provided in Table 2 .
| Cytogenetics results
Detailed cytogenetic results at the time of initial presentation and at the time of co-detection of BCR-ABL1 and CBFB rearrangements are provided in Table 3 . Case #1 had two clones at initial diagnosis: a clone with inv (16) 
| Molecular results
A p210 kD BCR-ABL1 product was identified in all cases in which BCR-ABL1 fusion preceded CBFB rearrangement, whereas a p190 kD product was identified in the other three cases. Among six cases analyzed for ABL1 kinase domain mutations, one case showed two distinct mutations (p.G254E and p.E329G). All evaluated cases were negative for FLT3 (n 5 5), NRAS and KRAS (n 5 4), and KIT (n 5 3) mutations.
| Treatment and outcome
Treatment details are provided in Table 1 . Briefly, two patients were treated with the FLAG-IDA regimen (fludarabine, cytarabine, idarubicin, and G-CSF) and TKIs; one of which ultimately received an allogeneic stem cell transplant. Seven patients were treated with cytarabinebased regimens and TKIs; in two of these patients treatment was followed by allogeneic stem cell transplant. One patient was treated with ponatinib alone. 46,idem,inv(16)(p13q22) [7] 47,XY,1Y [2] 46,idem,t(3;18)(p21;q23) [1] 46,XY [5] 41%: 59.5% 
| DISCUSSION
We describe 10 patients with simultaneous occurrence of BCR-ABL1
and CBFB rearrangement. The co-occurrence of BCR-ABL1 and CBFB rearrangement is an extremely rare event with less than a total of 20 cases reported in the literature. 18, 20, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] There is a male predominance, and the disease can present in any age, although patients tend to be older than those with AML with inv(16). 13 These patients can generally be classified into two major groups:
those who present with chronic phase CML and progress to CML-BP 39, 40 All of the cases evaluated in this series were wild type for these three genes, suggesting that the potent leukemogenic effect executed by the simultaneous presence of both chromosomal alterations precludes the need for additional somatic mutations for survival of the leukemic clone.
Based on their review of the literature, Ninomiya and colleagues suggested that de novo AML with BCR-ABL1 has a favorable prognosis when compared with other acute myeloid leukemias, similar to that of AML with inv(16) alone. 21 Two such patients were included in this cohort; one patient was treated with the FLAG-Ida regimen plus dasatinib and had a favorable clinical course and was in remission 21 months following presentation. The second patient was treated with the 3 1 7 regimen and tyrosine kinase inhibitors (details included in Table 1 ), relapsed 8 months after presentation and succumbed to disease two years following initial diagnosis. The prognosis of patients with CML and inv(16) as a secondary genetic alteration on the other hand seems to be very poor. 21 In fact, six of seven patients included in our series died despite intensive chemotherapy and targeted therapy with tyrosine kinase inhibitors (median OS from the time of inv(16): 14 months, range 4-85 months). One patient was alive and free of disease at the time of last follow-up; this patient was treated with the FLAG-IA regimen plus ponatinib and later received an allogeneic stem cell transplant. Although the number of patients in this series, and in the literature in general is too small to draw a definite conclusion, it appears that patients with concurrent inv (16) and BCR-ABL1 may benefit from intensive chemotherapy regimens such as the FLAG-Ida plus tyrosine kinase inhibitors.
